Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ART-400
- Development stage
- Preclinical
- Lead developer
- Arum Therapeutics
- Modality
- Small Molecules
01
Overview
ART-400 is a preclinical-stage small molecule anticancer immunotherapy being developed by Arum Therapeutics. The program focuses on the modulation of immune checkpoint molecules and cytokines to counteract the immunosuppressive tumor microenvironment and enhance the body's natural immune response against malignant cells. As of 2024, ART-400 is in the lead optimization phase, with the developer preparing for transition into Phase 1 clinical trials. By utilizing a small molecule modality, ART-400 aims to provide a differentiated therapeutic profile compared to existing antibody-based immunotherapies, potentially offering improved tumor penetration and the possibility of oral administration.
Beyond the preview
Go deeper on ART-400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ART-400.